# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Kazutoshi WATANABE et al.

Group Art Unit: 1614

Examiner: Unknown

벌 Sepial No : 09/787,426

July 2, 2001

For

: PYRIMIDONE DERIVATIVES

#### INFORMATION DISCLOSURE STATEMENT

Commissioner of Patents and Trademarks Washington, DC 20231

Sir:

In accordance with the duty of disclosure under 37 C.F.R. §§ 1.56, 1.97, and 1.98, Applicants hereby bring the following information to the attention of the Examiner in charge of the aboveidentified application, which includes information cited and discussed in the specification, in the International Search Report issued in connection with counterpart International Application No. PCT/JP99/05224, mailed January 21, 2000, in the International Preliminary Examination Report, mailed December 12, 2000, and in the Written Opinion, mailed May 9, 2001. Copies of the International Search Report and Written Opinion were submitted with the application. For the Examiner's convenience, Applicants are providing another copy of the International Search Report, the International Preliminary Examination Report and the Written Opinion.

EP 0 168 262, accompanied by U.S. family member U.S. Patent No. 4,725,600;

JP 6-239893, accompanied by an English language abstract;

JP 6-329551, accompanied by an English language abstract;

JP 49-35632;

JP 49-35634;

JP 52-071481, accompanied by an English language abstract;

WO 93/11231;

WO 98/24782;

Chemical Abstracts, Vol. 100, No. 28, 1984, Columbus, Ohio, US, Abstract No. 174768e, M.F. BRANA et al., "Reaction of N-(1-Oxido-4-Pyridylmethyl)-3,5-Dimethylbenzamide with Malononitrile in Acetic Anhydride", page 627; XP002127059;

Chemical Abstracts, Vol. 84, No. 7, 1976, Columbus, Ohio, US, Abstract No. 44112b, Tani et al., "4-Hydroxy-Pyridylpyrimidine Derivatives", Page 502, XP002127060;

Chemical Abstracts, Vol. 82, No. 28, 1975, Columbus, Ohio, US, Abstract No. 171028n, Tani et al., "2,4,5-Trisubstituted-6-Pyridylpyrimidine Derivatives", page 555, XP002127061;

Chemical Abstracts, Vol. 83, No. 28, 1975, Columbus, Ohio, US, Abstract No. 10127z, Tani et al., "5-Nitro-6-Pyridylpyrimidine Derivatives", page 853, XP002127062;

C.M. WISCHIK et al., "Isolation of a Fragment of Tau Derived from the core of the Paired Helical Filament of Alzheimer Disease", Proc. Natl. Acad. Sci. USA, Vol. 85, pp. 4506-4510 (1988);

Inge GRUNDKE-IQBAL et al., "Abnormal Phosphorylation of the Microtubule-Associated Protein τ (Tau) in Alzheimer Cytoskeletal Pathology", Proc. Natl. Acad. Sci. USA, Vol. 83, pp. 4913-4917 (1986);

Koichi ISHIGURO et al., "Tau Protein Kinase I Converts Normal Tau Protein into A68-like Component of Paired Helical Filaments", The Journal of Biological Chemistry, Vol. 267, No. 15, pp. 10897-10901 (1992);

Bruce A. YANKNER et al., "Neurotrophic and Neurotoxic Effects of Amyloid β Protein: Reversal by Tachykinin Neuropeptides", Science, Vol. 250, pp. 279-282 (1990);

Akihiko TAKASHIMA et al., "Tau Protein Kinase I is Essential for Amyloid β-Protein-Induced Neurotoxicity", Proc. Natl. Acad. Sci. USA, Vol. 90, pp. 7789-7793 (1993);

Von Hans-Joachim KABBE, "Substituierte 4-Hydroxy- und 4-Amino-Pyrimidine", Liebigs. Ann. Chem., Vol. 701, pp. 144-149 (1967); and

Harvey I. SKULNICK et al., "Pyrimidinones. 1. 2-Amino-5-Halo-6-Arly-4(3H)-Pyrimidinones. Interferon-Inducing Antiviral Agents", J. Med. Chem., Vol. 28, pp 1864-1869 (1985).

Copies of the above-noted documents are enclosed together with a duly completed Form PTO-1449. The Examiner is accordingly requested to consider each of these documents, and to make them of record in this application by initialing in the appropriate spaces on the Form-1449. Applicants respectfully request that the Examiner include a copy of the initialed Form PTO-1449 with the next communication from the U.S. Patent and Trademark Office.

Applicants note that while this Information Disclosure Statement is being filed more than three months from the filing date, Applicants have not received a first action on the merits from the U.S. Patent and Trademark Office. Accordingly, consideration of the enclosed document is required under 37 C.F.R. 1.97(b)(3).

However, if a first action on the merits has been mailed prior to the filing date of this Information Disclosure Statement, Applicants hereby authorize the Commissioner to charge any fees necessary to ensure consideration of the documents cited herein to Deposit Account No. 19-0089.

Any comments or questions concerning this application can be directed to the undersigned at the telephone number given below.

Respectfully submitted, Kazutoshi WATANABE et al.

Bruce H. Bernstein

Reg. No. 29,027

October 19, 2001 GREENBLUM & BERNSTEIN, P.L.C. 1941 Roland Clarke Place Reston, VA 20191 (703) 716-1191